Adas Darinskas – Innovita Research

Adas Darinskas, Ph.D., is a biotechnologist keen on cell technologies. After graduating the Vilnius University faculty of Natural Sciences, he got a master in molecular biology and defeated his Ph.D. theses in Immunology in the year 2008. The year 2015-2016 he graduated master program: Master degree in manufacturing of advanced therapy medicinal products, specialisation as qualified person (1,647 hours) related to the Master Programme in Manufacturing of Advanced Therapy Medicinal Products (Universidad de Granada/Iniciativa Andaluza en Terapias Avanzadas).

Main scientific interests:
Molecular mechanisms of aging, immunology and immune therapy in cancer and autoimmune diseases, regenerative medicine, gene and tissue engineering.

Skills:
Qualified person in advanced therapy medical product production and certification, mammalian cell culture, laboratory animal surgery and disease models, methods in molecular biology.

List of publications:

  • Scaffold design for artificial tissue with bone marrow stem cells.
    Noreikaitė A, Antanavičiūtė I, Mikalayeva V, Darinskas A, Tamulevičius T, Adomavičiūtė E, Šimatonis L, Akramienė D, Stankevičius E. Medicina (Kaunas).. 2017;53(3):203-210. doi: 10.1016/j.medici.2017.07.001.
    https://www.ncbi.nlm.nih.gov/pubmed/28774494
  • Stromal vascular fraction cells for the treatment of critical limb ischemia: a pilot study.
    Darinskas A, Paskevicius M, Apanavicius G, Vilkevicius G, Labanauskas L, Ichim TE, Rimdeika R. J Transl Med. 2017 Jun 19;15(1):143. doi: 10.1186/s12967-017-1243-3.
    https://www.ncbi.nlm.nih.gov/pubmed/28629476
  • Bacterial ghosts as adjuvants in syngeneic tumour cell lysate-based anticancer vaccination in a murine lung carcinoma model.
    Kraśko JA, Žilionytė K, Darinskas A, Strioga M, Rjabceva S, Zalutsky I, Derevyanko M, Kulchitsky V, Lubitz W, Kudela P, Miseikyte-Kaubriene E, Karaman O, Didenko H, Potebnya H, Chekhun V, Pašukonienė V.Oncol Rep. 2017 Jan;37(1):171-178. doi: 10.3892/or.2016.5252. Epub 2016 Nov 16.
    https://www.ncbi.nlm.nih.gov/pubmed/27878261
  • Preclinical study of SZ2080 material 3D microstructured scaffolds for cartilage tissue engineering made by femtosecond direct laser writing lithography.
    Mačiulaitis J, Deveikytė M, Rekštytė S, Bratchikov M, Darinskas A, Šimbelytė A, Daunoras G, Laurinavičienė A, Laurinavičius A, Gudas R, Malinauskas M, Mačiulaitis R. Biofabrication.. 2015 Mar 23;7(1):015015. doi: 10.1088/1758-5090/7/1/015015.
    https://www.ncbi.nlm.nih.gov/pubmed/25797444
  • Immune responses induced by T-cell vaccination in patients with rheumatoid arthritis.
    Ivanova I.P, Seledtsova G.V., Mamaev S.V., Shishkov A.A., Seledtsov V.I. Human Vaccines & Immunotherapeutics.. 2014; 10: 1-7.
    https://www.ncbi.nlm.nih.gov/pubmed/24633313
  • Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use?
    Strioga MM, Darinskas A, Pasukoniene V, Mlynska A, Ostapenko V, Schijns V. Vaccine.2014 Jul 7;32(32):4015-24. doi: 10.1016/j.vaccine.2014.05.006. Epub 2014 May 14. Review.
    https://www.ncbi.nlm.nih.gov/pubmed/24837511
  • Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells.
    Strioga M, Viswanathan S, Darinskas A, Slaby O, Michalek J. Stem Cells Dev.. 2012 Sep 20;21(14):2724-52. doi: 10.1089/scd.2011.0722. Epub 2012 May 9. Review.
    https://www.ncbi.nlm.nih.gov/pubmed/22468918
  • Protein oligomerization induced by oleic acid at the solid-liquid interface–equine lysozyme cytotoxic complexes.
    Wilhelm K, Darinskas A, Noppe W, Duchardt E, Mok KH, Vukojević V, Schleucher J, Morozova-Roche LA. FEBS J.. 2009 Aug;276(15):3975-89. doi: 10.1111/j.1742-4658.2009.07107.x. Epub 2009 Jul 7.
    https://www.ncbi.nlm.nih.gov/pubmed/19594832
  • Engrafting fetal liver cells into multiple tissues of healthy adult mice without the use of immunosuppressants.
    Darinskas A, Gasparaviciute R, Malisauskas M, Wilhelm K, Kozhevnikov JA, Liutkevicius E, Pilinkiene A, Morozova-Roche LA. Cell Mol Biol Lett. 2007 Sep;12(3):422-34. doi: 10.2478/s11658-007-0013-2. Epub 2007 May 10.
    https://www.ncbi.nlm.nih.gov/pubmed/17361367
  • Immune reactivity towards insulin, its amyloid and protein S100B in blood sera of Parkinson’s disease patients.
    Wilhelm KR, Yanamandra K, Gruden MA, Zamotin V, Malisauskas M, Casaite V, Darinskas A, Forsgren L, Morozova-Roche LA. Eur J Neurol. 2007 Mar;14(3):327-34.
    https://www.ncbi.nlm.nih.gov/pubmed/17355556
  • Intermediate amyloid oligomers of lysozyme: Is their cytotoxicity a particular case or general rule for amyloid?
    Malisauskas M, Darinskas A, Zamotin VV, Gharibyan A, Kostanyan IA, Morozova-Roche LA. Biochemistry (Mosc). 2006 May;71(5):505-12.
    https://www.ncbi.nlm.nih.gov/pubmed/16732728
  • Does the cytotoxic effect of transient amyloid oligomers from common equine lysozyme in vitro imply innate amyloid toxicity?
    Malisauskas M, Ostman J, Darinskas A, Zamotin V, Liutkevicius E, Lundgren E, Morozova-Roche LA. J Biol Chem. 2005 Feb 25;280(8):6269-75. Epub 2004 Dec 1.
    https://www.ncbi.nlm.nih.gov/pubmed/15576361

 

Patents:

  • Xenogenic normal tissue-derived vaccines for breaking the immune tolerance to tumor-associated, antigens.
    Seledtsov V.I., Darinskas A., Seledtsova G.V. Patent WO 2016046651 A1, 2016..